Rothschild Asset Management Inc. lowered its position in Revance Therapeutics, Inc. (NASDAQ:RVNC) by 4.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 54,166 shares of the biopharmaceutical company’s stock after selling 2,444 shares during the period. Rothschild Asset Management Inc.’s holdings in Revance Therapeutics were worth $1,430,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Goldman Sachs Group Inc. increased its stake in shares of Revance Therapeutics by 34.7% in the first quarter. Goldman Sachs Group Inc. now owns 548,650 shares of the biopharmaceutical company’s stock worth $11,412,000 after buying an additional 141,400 shares during the period. Bank of America Corp DE increased its stake in shares of Revance Therapeutics by 29.5% in the first quarter. Bank of America Corp DE now owns 7,247 shares of the biopharmaceutical company’s stock worth $151,000 after buying an additional 1,651 shares during the period. Schwab Charles Investment Management Inc. increased its stake in shares of Revance Therapeutics by 4.4% in the first quarter. Schwab Charles Investment Management Inc. now owns 92,490 shares of the biopharmaceutical company’s stock worth $1,924,000 after buying an additional 3,933 shares during the period. Geode Capital Management LLC increased its stake in shares of Revance Therapeutics by 16.4% in the first quarter. Geode Capital Management LLC now owns 178,435 shares of the biopharmaceutical company’s stock worth $3,711,000 after buying an additional 25,075 shares during the period. Finally, Vanguard Group Inc. increased its stake in shares of Revance Therapeutics by 5.1% in the first quarter. Vanguard Group Inc. now owns 868,118 shares of the biopharmaceutical company’s stock worth $18,056,000 after buying an additional 42,466 shares during the period. 87.29% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Revance Therapeutics, Inc. (RVNC) opened at 22.75 on Thursday. The stock’s market capitalization is $688.71 million. Revance Therapeutics, Inc. has a one year low of $12.35 and a one year high of $28.30. The company’s 50-day moving average is $24.56 and its 200-day moving average is $21.88.

Revance Therapeutics (NASDAQ:RVNC) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.93) by $0.03. The firm had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.05 million. Revance Therapeutics had a negative net margin of 32,936.67% and a negative return on equity of 55.21%. The company’s revenue was up .0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.88) EPS. On average, equities research analysts anticipate that Revance Therapeutics, Inc. will post ($3.80) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of United States and international copyright legislation. The legal version of this piece of content can be read at https://www.watchlistnews.com/revance-therapeutics-inc-rvnc-stake-reduced-by-rothschild-asset-management-inc/1468272.html.

A number of brokerages recently issued reports on RVNC. Zacks Investment Research raised shares of Revance Therapeutics from a “sell” rating to a “buy” rating and set a $25.00 price target on the stock in a report on Wednesday. Piper Jaffray Companies set a $28.00 price target on shares of Revance Therapeutics and gave the stock a “buy” rating in a report on Wednesday, July 26th. Cantor Fitzgerald began coverage on shares of Revance Therapeutics in a report on Thursday, July 20th. They set an “overweight” rating and a $50.00 price target on the stock. BidaskClub downgraded shares of Revance Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, July 12th. Finally, ValuEngine raised shares of Revance Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, June 9th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $34.75.

In related news, CEO L Daniel Browne sold 19,713 shares of the stock in a transaction that occurred on Wednesday, May 24th. The shares were sold at an average price of $20.35, for a total transaction of $401,159.55. Following the completion of the sale, the chief executive officer now owns 183,932 shares of the company’s stock, valued at approximately $3,743,016.20. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Lauren P. Silvernail sold 1,793 shares of the stock in a transaction that occurred on Monday, May 22nd. The stock was sold at an average price of $20.20, for a total transaction of $36,218.60. Following the sale, the chief financial officer now directly owns 36,566 shares of the company’s stock, valued at approximately $738,633.20. The disclosure for this sale can be found here. In the last three months, insiders have sold 33,793 shares of company stock valued at $685,576. Corporate insiders own 18.86% of the company’s stock.

About Revance Therapeutics

Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.

Want to see what other hedge funds are holding RVNC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revance Therapeutics, Inc. (NASDAQ:RVNC).

Institutional Ownership by Quarter for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.